• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Serentil (mesoridazine besylate)

Important labeling changes for all dosage forms of Serentil including a boxed WARNING to advise clinicians that Serentil has been shown to prolong the QTc interval in a dose related manner and drugs with this potential have been associated with torsade de pointes-type arrhythmias and sudden death.

[September 22, 2000 - Letter - Novartis]